JP2019520405A5 - - Google Patents

Download PDF

Info

Publication number
JP2019520405A5
JP2019520405A5 JP2019500483A JP2019500483A JP2019520405A5 JP 2019520405 A5 JP2019520405 A5 JP 2019520405A5 JP 2019500483 A JP2019500483 A JP 2019500483A JP 2019500483 A JP2019500483 A JP 2019500483A JP 2019520405 A5 JP2019520405 A5 JP 2019520405A5
Authority
JP
Japan
Prior art keywords
associated virus
adeno
recombinant adeno
vector
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019500483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520405A (ja
JP7493334B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/040735 external-priority patent/WO2018009553A1/en
Publication of JP2019520405A publication Critical patent/JP2019520405A/ja
Publication of JP2019520405A5 publication Critical patent/JP2019520405A5/ja
Priority to JP2022023711A priority Critical patent/JP2022084594A/ja
Application granted granted Critical
Publication of JP7493334B2 publication Critical patent/JP7493334B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019500483A 2016-07-05 2017-07-05 緑内障における神経保護療法としてのｓＦａｓＬのＡＡＶ２媒介遺伝子送達 Active JP7493334B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022023711A JP2022084594A (ja) 2016-07-05 2022-02-18 緑内障における神経保護療法としてのｓＦａｓＬのＡＡＶ２媒介遺伝子送達

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662358541P 2016-07-05 2016-07-05
US62/358,541 2016-07-05
US201762511629P 2017-05-26 2017-05-26
US62/511,629 2017-05-26
PCT/US2017/040735 WO2018009553A1 (en) 2016-07-05 2017-07-05 Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022023711A Division JP2022084594A (ja) 2016-07-05 2022-02-18 緑内障における神経保護療法としてのｓＦａｓＬのＡＡＶ２媒介遺伝子送達

Publications (3)

Publication Number Publication Date
JP2019520405A JP2019520405A (ja) 2019-07-18
JP2019520405A5 true JP2019520405A5 (https=) 2020-08-13
JP7493334B2 JP7493334B2 (ja) 2024-05-31

Family

ID=60912274

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019500483A Active JP7493334B2 (ja) 2016-07-05 2017-07-05 緑内障における神経保護療法としてのｓＦａｓＬのＡＡＶ２媒介遺伝子送達
JP2022023711A Pending JP2022084594A (ja) 2016-07-05 2022-02-18 緑内障における神経保護療法としてのｓＦａｓＬのＡＡＶ２媒介遺伝子送達

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022023711A Pending JP2022084594A (ja) 2016-07-05 2022-02-18 緑内障における神経保護療法としてのｓＦａｓＬのＡＡＶ２媒介遺伝子送達

Country Status (7)

Country Link
US (2) US20190240353A1 (https=)
EP (1) EP3481433B1 (https=)
JP (2) JP7493334B2 (https=)
KR (1) KR20190096329A (https=)
CN (1) CN110177577A (https=)
MX (1) MX2019000221A (https=)
WO (1) WO2018009553A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10508134B2 (en) 2015-05-01 2019-12-17 Onl Therapeutics, Inc. Peptide compositions and methods of use
EP3768301A4 (en) * 2018-03-20 2022-06-08 ONL Therapeutics, Inc. COMPOSITIONS AND METHODS FOR FAS INHIBITION
US10862211B2 (en) * 2018-08-21 2020-12-08 Htc Corporation Integrated antenna structure
US10818758B2 (en) 2018-11-16 2020-10-27 Asm Ip Holding B.V. Methods for forming a metal silicate film on a substrate in a reaction chamber and related semiconductor device structures
WO2023048529A1 (ko) * 2021-09-27 2023-03-30 (주) 씨드모젠 Aav2-f11 단백질을 유효성분으로 포함하는 녹내장 예방 또는 치료용 조성물
EP4456908A4 (en) * 2021-12-27 2025-08-27 Onl Therapeutics Inc SFASL TO INHIBIT RPE CELL DEATH AND ASSOCIATED DISORDERS
US20250213722A1 (en) * 2022-03-30 2025-07-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Adeno-associated virus vectors for nucleic acid delivery to retinal ganglion cells and/or retinal pigment epithelium cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
WO2002053703A2 (en) * 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
GB0820262D0 (en) * 2008-11-05 2008-12-10 Tmo Renewables Ltd Microorganisms
WO2012061045A2 (en) * 2010-11-01 2012-05-10 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving retinal ganglion cells
US9238679B2 (en) * 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EP2586793A1 (en) * 2011-10-27 2013-05-01 Centre National de la Recherche Scientifique Chimeric molecule involving oligomerized FasL extracellular domain
WO2014121093A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
ES2926774T3 (es) * 2013-03-15 2022-10-28 Univ North Carolina Chapel Hill Métodos y composiciones para vectores AAV de doble unión de glicano
US20160256571A1 (en) * 2013-09-30 2016-09-08 Sanofi Invention

Similar Documents

Publication Publication Date Title
JP2019520405A5 (https=)
JP2019089787A5 (https=)
JP2018520997A5 (https=)
JP2019537437A5 (https=)
PH12020550706A1 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
PH12018502387A1 (en) Adeno-associated virus variant capsids and methods of use thereof
JP2020028308A5 (https=)
WO2018022905A3 (en) Adeno-associated virus virions with variant capsid and methods of use thereof
PH12020550094A1 (en) Adeno-associated virus variant capsids and methods of use thereof
HRP20211024T4 (hr) Aav vektori za gensku terapiju mrežnice i cns-a
JP2019523648A5 (https=)
RU2019100525A (ru) Векторная система на основе аденоассоциированного вируса
JP2015523379A5 (https=)
JP2015501156A5 (https=)
JP2017538401A5 (https=)
RU2019139064A (ru) Композиции и способы для лечения цитомегаловируса
JP2019530462A5 (https=)
WO2012145601A3 (en) Adeno-associated virus virions with variant capsid and methods of use thereof
JP2020506710A5 (https=)
JP2018516869A5 (https=)
RU2020137429A (ru) Лечение пигментного ретинита
JP2021502978A5 (https=)
JP2017532965A5 (https=)
RU2020111038A (ru) Аденоассоциированные вирусные векторы для лечения миоцилиновой (myoc) глаукомы
US20250099554A1 (en) Compositions and methods of fas inhibition